Connect your AI

JBIO JBIO Proceeds from disposition of marketable securities and other investments

Proceeds from disposition of marketable securities and other investments at other companies

Johnson & JohnsonJNJ

$209M-4.1%

Kymera TherapeuticsKYMR

——

Other financials

Income statement

Operating income-$43.4M-85.8%

Net income-$40.4M-5.8%

EPS (diluted)-$0.57+95.3%

Balance sheet

Cash & equivalents$55.1M+24.6%

Total debt$808.0K+159%

Total equity$296.5M+455%

Total assets$319.4M+312%

Cash flow

Operating cash flow-$24.1M-28.4%

CapEx$3.0K—

Free cash flow-$33.7M—

Valuation

Market cap$1.33B+318%

Enterprise value$1.28B—

Returns & leverage

Return on equity-132.5%+120pp

Debt / equity0×—

Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's proceeds from disposition of marketable securities and other investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is JBIO's proceeds from disposition of marketable securities and other investments?: JBIO (JBIO) reported proceeds from disposition of marketable securities and other investments of $65.43M in Q1 2026.
How has JBIO's proceeds from disposition of marketable securities and other investments changed year-over-year?: JBIO's proceeds from disposition of marketable securities and other investments increased by 1715.6% year-over-year, from $3.6M to $65.43M.